Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

Abstract Background Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in China. The aim of this study was to evaluate the efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolo...

Full description

Bibliographic Details
Main Authors: Zhenmei An, Ting Lei, Lian Duan, Pei Hu, Zhongping Gou, Lihui Zhang, Lucie Durand-Gasselin, Nan Wang, Yan Wang, Feng Gu, on behalf of the LANTERN study investigators
Format: Article
Language:English
Published: BMC 2020-05-01
Series:BMC Endocrine Disorders
Subjects:
Acromegaly
Lanreotide autogel
Lanreotide
Somatostatin analogs
Chinese patients
Clinical trial
Online Access:http://link.springer.com/article/10.1186/s12902-020-0524-7

Internet

http://link.springer.com/article/10.1186/s12902-020-0524-7

Similar Items